Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: Role of inhibitory guanine nucleotide proteins

Journal of Molecular and Cellular Cardiology

Volumn 30, Issue 12, 1998, Pages 2669-2682

  Kouretas, Peter C ^a   Hannan, Robert L ^a   Kapur, Navin K ^a   Hendrickson, Richard ^a   Redmond, Eileen M ^a   Myers, Adam K ^a   Kim, Young D ^a   Cahill, Paul A ^a   Sitzmann, James V ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bovine endothelial cells; Gi proteins; Heparin; Nitric oxide; Non anticoagulant heparin

Indexed keywords

ACETYLCHOLINE; CITRULLINE; DEOXYCHOLATE SODIUM; HEPARIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; N ACETYLHEPARIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PERTUSSIS TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; THORACIC AORTA; VASCULAR ENDOTHELIUM; VASCULAR RING;

ANIMALIA; BOVINAE;

EID: 0032418130     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1998.0831     Document Type: Article

References (56)

1. ABILDGAARD U, 1968. Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest 21: 89-91.
2. BARZU T, LORMEAU JC, PETITOU M, MICHELSON S, CHOAY J, 1989. Heparin-derived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells. J Cell Physiol 140: 538-548.
3. BASHKIN P, DOCTROW S, KLAGSBRUN M, SVAHN CM, FOLKMAN J, VLODAVSKY I, 1989. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28: 1737-1743.
4. BLACK SC, GRALINSKI MR, FRIEDRICHS GS, KILGORE KS, DRISCOLL EM, LUCCHESI BR, 1995. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 29: 629-636.
5. BRADFORD MM, 1976. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein dye binding. Ann Biochem 72: 248-254.
6. BREDT DS, SNYDER SH. 1990. Isolation of nitric oxide synthase: a calcium-requiring enzyme Proc Natl Acad Sci USA 87: 682-685.
7. CAHILL PA, REDMOND EM, FOSTER C, SITZMANN JV. 1995. Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. Eur J Pharmacol 288: 219-229.
8. CAHILL PA, WU Y, SITZMANN JV. 1994. Altered adenylyl cyclase activities and G-protein abnormalities in portal hypertensive rabbits. J Clin Invest 93: 2691-2700.44.
9. COFRANCESCO E, RADAELLI F, POGLIANI E. 1979. Correlation of sulfate content and degree of carboxylation of heparin and related glycosaminoglycans with anti-complement activity. Relationships to the anti-coagulant and platelet-aggregating activities. Thromb Res 14: 179-187.
10. CUSMA-PELOGIA N, OLIVEIRA SF, NIGRO D, DE CARVALHO MH, SCIVOLETTO R, FORTES ZB. 1993. Endothelium inactivation in in vitro perfused vascular beds. Comparison of methods. J Pharmacol Toxicol Methods 29: 157-163.
11. DASSO LL, TAYLOR CW. 1991. Heparin and other polyanions uncouple alpha 1-adrenoceptors from G-proteins. Biochem J 280: 791-795.
12. EKRE HP, NAPARSTEK Y, LIDER O, HYDEN P, HAGERMARK O, NILSSON T, VLODAVSKY I, COHEN I. 1992. Antiinflammatory effects of heparin and its derivatives: inhibition of complement and lymphocyte migration. Adv Exp Med Biol 313: 329-340.
13. ELBEIN AD, 1974. Interactions of polynucleotides and other poly electrolytes with enzymes and other proteins. Advan Enzymol 40: 29-64.
14. EVORA PR, PEARSON PJ, SCHAFF HV. 1994. Impaired endothelium-dependent relaxation after coronary reperfusion injury: evidence for G-protein dysfunction. Ann Thoracic Surg 57: 1550-1556.
15. FLAVAHAN NA, SHIMONOKA H, VANHOUTTE PM, 1989. Pertussis toxin inhibits endothelium-dependent relaxations to certain agonists in porcine coronary arteries. J Physiol (Lond) 408: 549-560.
16. FLAVAHAN NA, VANHOUTTE PM, 1990. G-proteins and endothelial responses. Blood Vessels 27: 218-229.
17. FOLKMAN J, KLAGSBRUN M, SASSE J, WADZINSKI M, INGBER D, VLODAVSKY I, 1988. A heparin-binding angiogenic protein - basic flbroblast growth factor - is stored within basement membrane. Am J Pathol 130: 393-400.
18. FRIEDRICHS GS, KILGORE KS, MANLEY PJ, GRALINSKI MR, LUCCHESI BR. 1994. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 75: 701-710.
19. GAUTHIER TW, DAVENPECK KL, LEFER AM. 1994. Nitric oxide attenuates leukocyte-endothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am J Physiol 267: G562-G568.
20. GUYTON JR, ROSENBERG RD, CLOWES AW, KARNOVSKY MJ. 1980. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anti-coagulant and nonanticoagulant heparin. Circ Res 46: 625-634.
21. HANNAN RL, KOURETAS PC, KIM YD, MYERS JL, TO LN, WANG YN, WALLACE RB. 1997. Heparin preserves coronary endothelial function after ischemia-reperfusion injury independent of its anticoagulant properties. FASEB J 11: A283.
22. HERSH LS, WEETALL HH, BROWN IW, JR. 1969. Heparin ionically linked to glass. J Biomed Mater Res 3: 471-474.
23. HOBSON RW, WRIGHT JG, FOX D, KERR JC. 1998. Heparinization reduces endothelial permeability and hydrogen ion accumulation in a canine skeletal muscle in ischemia-reperfusion model. J Vasc Surg 7: 585-591.
24. HOOVER RL, ROSENBERG W, HAERING W, KARNOVSKY MJ. 1980. Inhibition of rat smooth muscle proliferation by heparin. Circ Res 47: 578-583.
25. HOU M-C, CAHILL PA, ZHANG S, REDMOND EM, SITZMANN JV. 1997. Enhanced G-protein-induced relaxation in portal hypertensive rats: role of nitric oxide. Hepatology 26: 27-33.
26. IMAI T, HIRATA Y, EMORI T, MARUMO F. 1993. Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. 21: 353-358.
27. ITO H, TAKIKAWA R, IGUCHI M, HAMADA E, SUGIMOTO T, KURACHI Y, 1990. Heparin uncouples the muscarinic receptors from GK protein in the atrial cell membrane of the guinea-pig heart. Pflügers Arch 417: 126-128.
28. JAQUES LB. 1967. The pharmacology of heparin and heparinoids. Progr Med Chem 5: 139-198.
29. KAZATCHKINE MD, FEARON DT, METCALFE DD, ROSENBERG RD, AUSTEN KF, 1981. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 67: 223-228.
30. KUROSE I, WOLF R, GRISHAM MB, GRANGER DN. 1994. Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 74: 376-382.
31. LEFER AM, SIEGFRIED MR, MA XL. 1993. Protection of ischemia-reperfusion injury by sydnonimine NO donors via inhibition of neutrophil-endothelium interaction. J Cardiovasc Pharm 22 Suppl 7: S27-S33.
32. LI JM, HAJARIZADEH H, LA ROSA CA, ROHRER MJ, VANDER SALM TJ, CUTLER BS, 1996. Heparin and protamine stimulate the production of nitric oxide. J Cardiovasc Surg 37: 445-452.
33. LIAO JK, HOMCY CJ. 1992. Specific receptor-guanine nucleotide binding protein interaction mediates the release of endothelium derived relaxing factor. Circ Res 70: 1018-1026.
34. LINDAHL TJ, BACKSTROM G, HOOK M, THUNBERG L, FRANSSON LA, LINKER A, 1979. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 76: 3198-3202.
35. MA XL, WEYRICH AS, LEFER DJ, LEFER AM. 1993. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 72: 403-412.
36. MINAMI M, YOKOKAWA K, KOHNO M, IKEDA M, HORIO T, KANO H, HANEHIRA T, YASUNARI K, TAKEDA T. 1995. Promotion of nitric oxide formation by heparin in cultured aortic endothelial cells from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 22 Suppl 1: S146-S147.
37. NIROOMAND F, WEINBRENNER C, WEIS A, BANGERT M, SCHWENCKE C, MARQUETANT R, BEYER T, STRASSER RH, KUBLER W, RAUCH B, 1995. Impaired function of inhibitory G proteins during acute myocardial ischemia of canine hearts and its reversal during reperfusion and a second period of ischemia. Possible implications for the protective mechanism of ischemic preconditioning. Circ Res 76: 861-870.
38. OHNO M, GIBBONS GH, DZAU VJ, COOKE JD. 1993. Shear stress elevated endothelial cGMP. Role of a potassium channel and G-protein coupling. Circulation 88: 193-197.
39. PIATTI PM, MONTI LD, VALSECCHI G, CONTI M, NASSER R, GUAZZINI B, FOCHESATO E, PHAN CV, PONTIROLI AE, POZZA G. 1996. Effects of low-dose heparin infusion on arterial endothelin-1 release in humans. Circulation 94: 2703-2707.
40. RANA MW, SINGH G, WANG P, AYALA A, ZHOU M, CHAUDRY IH. 1992. Protective effects of preheparinization on the microvasculature during and after hemorrhagic shock. J Trauma 32: 420-426.
41. REANTRAGOON S, ARRIGO LM, SEOUD MM, DWECK HS, ROSENFELD L, 1994. Specific heparin fractions suppress endothelin-1 production in cultured human umbilical vein endothelial cells. Arch Biochem Biophys 314: 315-322.
42. ROSENBERG RD, LAM L. 1979. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 76:1218-1222.
43. ROSENGART TK, KUPERSCHMID JP, MACIAG T, CLARK RE. 1989. Pharmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat. Circ Res 64: 227-234.
44. SIEGFRIED MR, ERHARDT J, RIDER T, MA XL, LEFER AM. 1992. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharm Exper Ther 260: 668-675.
45. STERNBERGH WC, III, MAKHOUL RG, ADELMAN B, 1993. Heparin prevents postischemic endothelial cell dysfunction by a mechanism independent of its anti-coagulant activity. J Vasc Surg 17: 318-327.
46. STERNBERGH WC, III, SOBEL M, MAKHOUL RG. 1995. Heparinoids with low anticoagulant potency attenuate postischemic endothelial cell dysfunction. J Vasc Surg 21: 477-483.
47. SUMMERS ST, ZINNER MJ, FREISCHLAG JA. 1993. Production of endothelium-derived relaxing factor (EDRF) is compromised after ischemia and reperfusion. Am J Surg 166: 216-220.
48. TUNBRIDGE LJ, LLOYD JV, PENHALL RK, WISE AL, MALONEY T. 1981. Stability of diluted heparin sodium stored in plastic syringes. Am J Hosp Pharm 38: 1001-1004.
49. UPCHURCH GR, WELCH GN, FREEDMAN JE, FABIAN AJ, PIGAZZI A, SCRIBNER AM, ALPERT CS, KEANEY JF, LOSCALZO J, 1997. High dose of heparin decreases nitric oxide production by cultured bovine endothelial cells. Circulation 95: 2115-2121.
50. WANG P, SINGH G, RANA MW, BA ZF, CHAUDRY IH, 1990. Preheparinization improves organ function after hemorrhage and resuscitation. Am J Physiol 259: R645-R650.
51. WANG SZ, EDMUNDSON R, ZHU SZ, EL-FAKAHANY EE. 1996. Selective enhancement of antagonist ligand binding at muscarinic M2 receptors by heparin due to receptor uncoupling. Eur J Pharmacol 296: 113-118.
52. WILLUWEIT B, AKTORIES K. 1998. Heparin uncouples alpha 2-adrenoceptors from the Gi-protein membranes of human platelets. Biochem J 249: 857-863.
53. WRIGHT JG, KERR JC, VALERI CR, HOBSON RW, 1998. Heparin decreases ischemia-reperfusion injury in isolated canine gracilis model. Arch Surg 123: 470-472.
54. YOKOKAWA K, MANDAL AK, KOKNO M, HORIO T, MURAKAWA K, YASUNARI K, TAKEDA T, 1992. Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats. Am J Physiol 263: R1035-R1041.
55. YOKOKAWA K, TAHARA H, KOHNO M, MANDAL AK, YANAGISAWA M, TAKEDA T, 1993. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 92: 2080-2085.
56. YOKOKAWA K, MANKUS R, SAKLAYEN MG, KOHNO M, YASUNARI K, MINAMI M, KANO H, HORIO T, TAKEDA T, MANDEL AK. 1995. Increased nitric oxide production in patients with hypotension during hemodialysis [see comments]. Ann Intern Med 123: 35-37.